

TITLE

Medical Oncology Group of Australia Limited
Annual Scientific Meeting 2011, 10-12 August 2011

Advances in Cancer Care-Cost and value

ESMO supported Meeting

Adelaide Convention Centre
North Terrace
Adelaide South Australia

INTRODUCTION

Since 1979 the Medical Oncology Group of Australia (MOGA) has presented an Annual Scientific Meeting. The purpose of this meeting is to present a scientifically robust professional meeting which provides valuable networking, educational and training opportunities for professionals involved in the management of cancer in Australia and the Asia Pacific Region.

Each year a full and extensive scientific program is planned under the guidance of an expert planning committee. The Meeting includes a series of professional meetings, Supervisor and Communications Skills Training and a half-day Trainee Program incorporating workshops in key areas of clinical practice, lectures, discussion sessions and practical skills training session. This is followed by two days of scientific sessions covering recent developments in clinical practice. Featured international speakers present keynote addresses and participate in special panel sessions joined by local and national speakers. The scientific program includes a number of social functions notably the Conference Dinner. A corporate exhibition component including up to 30 display booths also forms part of the Meeting. Best of ASCO Australia has been the final element of the Meeting since 2009.

Each year up to 250 delegates from the medical and scientific community including representatives from various scientific, pharmaceutical and medical companies in Australia and New Zealand attend the Annual Scientific Meeting.

MOGA actively pursues professional collaborations with other professional organisations in Australia and every second year has held a joint meeting with affiliated organisations such as the Faculty of Radiation Oncology and the Cancer Nurses of Australia. In 2008 the Association worked with the three scientific and medical professional collegiate organisations in New Zealand, the Faculty of Radiation Oncology (Royal Australian and New Zealand College of Radiation), the New Zealand Society for Oncology (NZSO) and the New Zealand Association of Cancer Specialists (NZACS), to present a joint scientific meeting. In 2010 the Association partnered with the Private Cancer Physicians of Australia tp present a joint Meeting.

PLANNING COMMITTEE

Associate Professor Chris Karapetis, *Convenor*

Senior Consultant Medical Oncologist, Flinders Medical Centre

Professor Michael Brown

Consultant Medical Oncologist, Royal Adelaide Hospital Cancer Centre

Dr Kerry Cheong

Medical Oncologist, Adelaide Cancer Centre

Professor Bogda Koczwara

Head of Department of Medical Oncology, Flinders Medical Centre, Adelaide

Professor Ian Olver

Chief Executive Officer, Cancer Council Australia

Professor Ken Pittman

Director Medical Oncology, Queen Elizabeth Hospital, Adelaide

Associate Professor Timothy Price

Head of Clinical Oncology Research, Queen Elizabeth Hospital, Adelaide

Dr Professor Sid Selva-Nayagam

Director of Medical Oncology, Royal Adelaide Hospital Cancer Centre

Ms Kay Francis

Executive Officer, Medical Oncology Group of Australia Incorporated

INVITED SPEAKERS

INTERNATIONAL

Professor Michel Ducreux

Institut Gustave Roussy

Villejuif, France

Associate Professor Natasha Leighl

Princess Margaret Hospital

Toronto, Ontario, CA

Professor Tony Mok

Sir Yue-Kong Pao Centre for Cancer

New Territories, Hong Kong

ESMO Supported Meeting Speaker and Representative

Professor Marianne Pavel

Charité University

Berlin, Germany

Associate Professor Deborah Schrag

Dana-Farber Cancer Institute

Boston, MA, USA

NATIONAL

Dr Yu Jo Chua

Medical Oncology Unit, Canberra Hospital

Woden, ACT

Professor Rodney Hicks

Peter MacCallum Cancer Centre

Melbourne, VIC

Dr John Leyden

The Unicorn Foundation

Mosman, NSW

Associate Professor Lara Lipton

Royal Melbourne and Western Hospitals

Ludwig Institute for Cancer Research

Parkville, VIC

Dr Jeremy Shapiro

Monash University

Melbourne, VIC

Professor Harvey Turner

Fremantle Hospital

Department of Nuclear Medicine

Fremantle, WA

Professor Paul Waring

The University of Melbourne

Melbourne

CONFERENCE THEME AND AIMS

The main theme of the 2011 MOGA ASM was *Advances in Cancer Care-Cost and Value* and focused on the issue that significant developments in oncology also present major challenges with respect to resource utilisation, equitable access and financial burden. These issues were examined throughout the meeting in breakfast sessions, special symposia and oral presentations. International guest speakers including Natasha Leighl (Canada), Tony Mok (Hong Kong), Michel Ducreux (France), Deborah Schrag (USA) and Marianne Pavel (Germany) examined these core issues in various sessions in addition to delivering presentations of their key areas of oncology specialisation. The main tumour types explored at the meeting included lung cancer, colorectal cancer and neuroendocrine tumours. The program also included will oral and poster presentations, debates and breakfast meetings. The program aimed to stimulate and educate all those with an interest in the ever expanding and rapidly developing field of Medical Oncology at all professional levels. Australian Medical Oncology professional achievements and research was highlighted at the meeting and positioned along side international endeavours. The meeting provided a valuable opportunity for Australian oncology and related professional groups and pharmaceutical industry to review the most current international and national research developments interact with colleagues, develop professional networks and enhance their professional skills as well as knowledge bases.

SCIENTIFIC PROGRAM

Wednesday 10 August 2011

9.00 am–12.30 pm CREST Workshop: Understanding Health Economics in Cancer Research

Presenters: Alison Pearce and Rosalie Viney

11.00 am–4.00 pm ALTG Trials Group Meeting

12.00 pm–3.45 pm Advanced Trainees Education Program

Co-Chairs: Matteo Carlino and Diana Adams

12.00 pm–12.30 pm Registration & Lunch

12.30 pm–1.00 pm Advanced Trainee Update-Special Advisory Committee, RACP

Presenter: Linda Mileschkin

1.00 pm–1.30 pm Designing and Managing Surveys

Presenter: Linda Mileschkin

1.30 pm–2.00 pm Radiation Oncology for Medical Oncologists

Presenter: TBC

2.00 pm–2.30 pm Australia and Asia Pacific Clinical Oncology Research Development Workshop

(ACORD)- Clinical Trials Research Training

Presenters: Martin Stockler and Hilary Martin

2.30 pm–2.45 pm Afternoon Tea

2.45 pm–3.15 pm Prognostication-Case Based Approach

Presenter: Belinda Kiely

3.15 pm–4.00 pm Discussion

12.30 pm–4.00 pm RACP Supervisors Training Workshop

12.30 pm–4.00 pm Communication Skills Workshop (Advanced Trainees in Medical Oncology Only)

3.30 pm MOGA ASM Registration Open

4.00 pm–5.00 pm Industry Symposium

Access to New Drugs

Chair: Ian Olver

Access to co-dependent technologies

Presenter: Michael Rasmussen

The MOGA advocacy agenda for drug availability

Presenter: Michael Michael

5.00 pm–6.30 pm Sponsor Symposium – Roche & Boehringer Ingelheim Joint Lung Symposium

Treating Advanced NSCLC with Targeted Therapies

Chair: Ken Pittman

What's new?

Presenter: Tony Mok

What should I do?

Presenter: Natasha Leighl
6.30 pm–7.30 pm Welcome Reception
8.00 pm–11.00 pm GSK Advanced Trainees Dinner

Thursday 11 August 2011

Concurrent Breakfast Sessions

7.30 am–8.30 am Challenges in diagnostic NET management

Chair: Michael Brown

Presenter: Marianne Pavel

7.30 am–8.30 am What is an appropriate primary endpoint for lung cancer studies?

Chair: Shawgi Sukumaran

Presenter: Tony Mok

7.30 am–8.30 am Advances in Breast Cancer Care

Chair: Kerry Cheong

Presenter: Natasha Leighl

8.45 am–9.00 am Welcome to Country and Official Opening Ceremony

Official Opening

Speaker: Mr Hieu Van Le A.O Pls add full title

9.00 am–10.45 am Symposium 1: Advances in Lung Cancer Management – The Cost of Progress

Chair: Rick DeBoer

9.00 am Advances in first line therapy

Presenter: Tony Mok

9.40 am Advances in maintenance therapy and beyond

Presenter: Natasha Leighl

10.45 am–11.15 am Morning Tea

11.15 am–12.45 am Symposium 2 – Neuroendocrine Tumours – Diagnosis, Treatment and Progress in 2011 and Beyond – Session 1

Chair: Gabby Cehic

11.15 am Recent advances in medical therapy for Neuroendocrine Tumours

Presenter: Marianne Pavel

12.00 am Multimodality Radiopeptide Therapy of Disseminated Neuroendocrine Tumour

Presenter: Harvey Turner

12.20 am Open misere to royal flush; how do we choose between competing therapies for NET?

Presenter: Rodney Hicks

12.45 am–1.45 pm Lunch

12.45 pm MOGA Annual General Meeting

1.45 pm–3.00 pm Oral Presentation Session 1 – Trainees

Chair: Martin Stockler

The Pattern of Care for Malignant Pleural Mesothelioma (MPM) Patients in Australia

Presenter: Steven Kao

Ambulatory Care of Low-risk Patients with Neutropenic Fever: An Australian Pilot Study

Presenter: Christopher Hocking

Survival differences in metastatic colorectal cancer patients with single site metastatic disease: Results from South Australian Clinical Registry for Advanced Colorectal Cancer

Presenter: Muhammad Khattak

Tele Oncology Clinics in Rural Queensland: a Cost-effective Cancer Care Model

Presenter: Darshit Thacker

Nausea Still the Poor Relation in Antiemetic Therapy, Risk Factors at Pretreatment

Predicting Treatment-Induced Nausea and Vomiting in Australian Cancer Patients: A Prospective, Longitudinal, Observational Study

Presenter: Carlo Pirri

Polypharmacy in the Terminally Ill

Presenter: Ross Cruikshank

Benefits and Harms of Radiotherapy for Rectal Cancer: Meta-analysis of survival and toxicity

Presenter: Aparna Rao

3.00 pm–3.30 pm Afternoon Tea
 3.30 pm–4.30 pm Viewpoint Session – CAM Debate
 An expert on complementary and alternative medicine is an essential member of a comprehensive cancer centre
 Chair: Bogda Koczwara
 Discussants: Ray Lowenthal and David Joske
 4.30 pm–5.30 pm Oral Presentation Session 2 – Consultants
 Chair: Chris Karapetis
 Patterns of Care for Stage-1 Testicular Cancer in Australia in 2010
 Presenter: Baerin Houghton
 Sexual Wellbeing and Breast Cancer in Australia: the experiences of people with breast cancer
 Presenter: Michelle Marven
 Geriatric assessment of older patients with cancer in Australia: A national, multicentre audit
 Presenter: Christopher Steer
 Whole Brain Radiotherapy Following Local Treatment of 1–3 Intracranial Metastases of Melanoma – A Phase III Trial (ANZMTG 01/07; TROG 08/05)
 Presenter: Gerald Fogarty
 Accelerated BEP for advanced germ cell tumours: An Australian multicentre phase I/II trial
 Presenter: Peter Grimison
 5.30 pm–6.30 pm Poster Walk Around Session
 6.30 pm–8.30 pm Platinum Sponsor Cocktail Party

Friday 12 August 2011

Concurrent Breakfast Sessions
 7.30 am–8.30 am Multimodality treatment decision making in Rectal cancer
 Chair: Ben Markman
 Presenter: Deborah Schrag
 7.30 am–8.30 am Title TBC
 Chair: Sid Selva-Nayagam
 Presenter: Michel Ducreux
 7.30 am–8.30 am Industry Breakfast
 9.00 am–10.30 am Symposium 3 – Predictive and Prognostic – Making sense of Bio-markers in Colorectal Cancer
 Chair: Chris Karapetis
 9.00 am Prognostic and Predictive Markers in Colon Cancer: When and How they are used for treatment decision making in the USA
 Presenter: Deborah Schrag
 9.20 am Biomarkers in colorectal cancer – How accurately do they mark?
 Presenter: Lara Lipton
 10.00 am A pathologist’s perspective on biomarkers in colorectal cancer
 Presenter: Paul Waring
 10.30 am–11.00 am Morning Tea
 11.00 am–12.00 pm Symposium 4 – The Cost and the Value of Treating Advanced Cancer with Non-Curative
 New Therapies
 Chair: Michael Michael
 11.00 am Identifying High Value Cancer Treatments: Patient, Physician and Public Health System Perspectives
 Presenter: Deborah Schrag
 11.30 am High costs drugs in Australia – Navigating between Evidence, Economics and Need
 Presenter: Jeremy Shapiro
 12.00 pm–12.30 pm Cancer Achievement Award Presentation
 12.30 pm–1.30 pm Lunch
 12.30 pm Trainees Meeting

Scientific Program – Friday 25

12.30 pm–2.00 pm Cancer Council New South Wales Meeting – Cancer of Unknown Primary Steering Group Meeting

1.30 pm–3.00 pm Oral Presentation Session 3 – Plenary Session

Chair: Ian Olver

Factors affecting time from surgery to adjuvant chemotherapy for early breast cancer in a rural and urban medical oncology unit: a retrospective cohort study

Presenter: Peter Fox

Cost-effectiveness of universal Hepatitis B virus screening in patients beginning chemotherapy for solid tumours

Presenter: Fiona Day

Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases

Presenter: Matteo Carlino

RAS mutations in keratinocytes interact with BRAF-inhibitor therapy to promote squamous cell tumor formation

Presenter: Damien Kee

Prognostic significance of plasma osteopontin in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated on TROG 02.02 Phase III trial

Presenter: Annette Lin

The inflammatory marker neutrophil lymphocyte ratio (NLR) predicts outcomes from chemotherapy in colorectal cancer (CRC), mesothelioma (MM) and non-small cell lung cancer (NSCLC) patients receiving chemotherapy

Presenter: Stephen Clarke

3.00 pm–3.30 pm Afternoon Tea

3.30 pm–5.00 pm Symposium 5 – Neuroendocrine Tumours – Diagnosis, Treatment and Progress in 2011 and

Beyond – Session 2

Chair: Tim Price

4.15 pm NET Cancer Management – Meeting our KPIs (Key patient indices)

Presenter: John Leyden

4.35 pm Advancing the management of NETs in Australia

Presenter: Yu Jo Chua

5.00 pm Close of Sessions

7.00 pm Conference Gala Dinner

Venue: South Australia State Library

VIRTUAL MEETING

The proceeding of the meeting were not presented and made available in any virtual meeting format. An audio recording and presenters' slides was made and are available in the Members only section of the MOGA website.

LOGO

There was no meeting logo. The meeting was branded with the MOGA logo with the addition of the ESMO logo.

PARTICIPANTS AND MEETING EVALUATION

The Meeting was attended by 325 attendees including Australian medical oncology consultants and trainees, medical oncology and radiation oncology guest speakers and representatives of consumer and allied health organisations as well as the pharmaceutical industry.

DELEGATES

The meeting was attended by 325 delegates. These included 85 medical oncologists, 71 trainees in medical oncology, 71 medical specialists from a range of oncology disciplines as well as 24 scientists, allied health workers and nurses. The meeting also included 74 industry representatives. 50% of the Australian oncology consultant delegates were members of ESMO.

POSTER AND PRESENTATION PRIZES

Amgen Australia generously provided 4 meeting poster and presentation prizes to be awarded to trainees and consultants. The quality of the posters and presentations was of a very high standard.

EVALUATION

The meeting Evaluation report is attached.

CONCLUSION

The 2011 Annual Scientific Meeting was well received and reviewed by the Australian Medical Oncology profession. MOGA would like to express our appreciation and thanks to the many individuals and organisations that assisted with the development and planning of this important scientific meeting. In particular, we would like to recognise and thank the ESMO for designating the meeting an ESMO supported meeting, providing ESMO certificates for all delegates and supporting the participation of Professor Tony Mok as a key international speaker.



Gala Dinner Official Party, from left to right: Dr Mustafa Khaaraw, Dr Matteo Carlini, Dr John Leyden, Dr Marianne Pavel, Associate Professor Michael Michael, Dr Rosemary Harrup, Mrs Lynnette Zalberg, Dr Linda Mileshkin, Professor John R. Zalberg, Professor Michel Ducreux, Mr Brian Gladtsden, Professor Ian Oliver, Mrs Jenny Oliver, Ms Simone Leyden, Dr Christopher Steer, Professor Ray Lowenthal, Associate Professor Gary Richardson, Associate Professor Chris Karapetis, Dr Tim Price, Dr Ken Pittman & Dr Diana Adams

Prof. Dorothy Keefe, A/Prof. Chris Karapetis & Dr Sid Selva-Nayagam



Mrs Lynnette & Prof. John R. Zalberg, Mr Kevin Thomas, Mr Brian Gladtsden & A/Prof Gary Richardson



Prof. Dorothy Keefe, A/Prof. Chris Karapetis & Dr Sid Selva-Nayagam

MOGA ASM Evaluation

Please enter your name to go into the draw to win an Apple iPad	
Answer Options	Response Count
	42
<i>answered question</i>	42
<i>skipped question</i>	2

Response Text
Grace Malanos
Gabrielle Cehic
Marcin Dzienis
Rachel Roberts-Thomson
Andrea Tazbirkova
Meena Okera
Lesley Roberts
Kaye Roberts
Ian Olver
Muhammad Adnan Khattak
Kerrie Vaughan
Christopher Pene
Peter Savas
Ross Cruikshank
Kasia Chmiel
Kiley Loh
Lorna Rogers
Susie Bae
Felicity Young
Martin Stockler
Mitchell Quinlivan
Dr Suresh Varma
Damien Kee
Michael Kitchener
Katrin Sjoquist
Samantha bowyer
Hui-li Wong
Anne Taylor
Amit Sharma
Chek Poh Beh
Susan Caird
Steven Kao
Stephanie Lim
Stephen Clarke
Dr John Leyden
Valerie heong
Bala Chittajallu
Eddy Thientosapol
Peter Fox
Adnan Nagrial
Rod Hicks

Occupation		
Answer Options	Response Percent	Response Count
Medical Oncologist	80.0%	24
Radiation Oncologist	0.0%	0
Surgeon	0.0%	0
Pharmacist	0.0%	0
Nurse	0.0%	0
Pharmaceutical company	20.0%	6
Other (please specify)		18
<i>answered question</i>		30
<i>skipped question</i>		14

Other (please specify)
Nuclear medicine Physician
Medical Oncology Registrar
Medical Oncology Advanced Trainee
Advanced Trainee in Medical Oncology
Advanced Trainee
Medical Oncology Registrar
Medical Oncology Trainee
Nuclear Physician
Medical oncology trainee
Medical Oncology trainee
Radiologist
Registrar
Advanced trainee
Chairman, The Unicorn Foundation
Medical Oncology Trainee
Registrar
Medical Oncology trainee
Nuclear medicine physician

Speciality (please specify)
Oncology
Therapeutic Nuclear Oncology
trainee
Oncology
Oncology
Oncology
Advocacy
Medical oncology
oncology, palliative care
Medical Oncology
Palliative Care
Advanced Trainee
Medical oncology
Oncology
Medical Oncology
Medical Oncology and Clinical Trials
Medical Writing
Medical Oncology
Skin
Nuclear Medicine
General/Gastrointestinal/Gynae/Breast
Medical oncology
Medical Oncology
breast, head & neck, colorectal
Trainee
Radiologists
Medical Oncology
medical oncologist
Medical Oncology
Colon/Lung/Mesothelioma
Anaesthesia
Medical Oncology (general)
Medical Oncology
Medical oncology
Breast
Upper GI
Cancer Imaging

State/Country of Residence		
Answer Options	Response Percent	Response Count
ACT	0.0%	0
NSW	37.2%	16
VIC	14.0%	6
TAS	0.0%	0
SA	20.9%	9
NT	2.3%	1
WA	4.7%	2
QLD	18.6%	8
New Zealand	2.3%	1
Other (please specify)		0
<i>answered question</i>		43
<i>skipped question</i>		1

Membership		
Answer Options	Response Percent	Response Count
MOGA Member	75.0%	33
Non-member	25.0%	11
<i>answered question</i>		44
<i>skipped question</i>		0

Did you attend the 2011 Best of ASCO® Meeting?		
Answer Options	Response Percent	Response Count
Yes	63.6%	28
No	36.4%	16
<i>answered question</i>		44
<i>skipped question</i>		0

Industry Symposium - Access to New Drugs							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	1	3	16	5	4	3.28	29
Speaker's delivery	0	3	16	6	4	3.38	29
Relevance	0	3	14	6	6	3.52	29
<i>answered question</i>							29
<i>skipped question</i>							15

Roche & Boehringer Ingelheim Joint Lung Symposium							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	3	5	16	5	3.79	29
Speaker's delivery	0	2	8	11	8	3.86	29
Relevance	0	1	6	15	7	3.97	29
<i>answered question</i>							29
<i>skipped question</i>							15

Concurrent Breakfast 1 - Neuroendocrine Tumours Challenges in diagnostic NET management Prof Marianne Pavel							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	0	8	8	3	3.74	19
Speaker's delivery	0	1	7	8	3	3.68	19
Relevance	0	0	7	8	4	3.84	19
<i>answered question</i>							19
<i>skipped question</i>							25

Concurrent Breakfast 2 - Lung Cancer What is an appropriate primary endpoint for lung cancer studies? Prof Tony Mok							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	1	3	9	4	3.94	17
Speaker's delivery	0	1	2	8	6	4.12	17
Relevance	0	1	1	10	5	4.12	17
<i>answered question</i>							17
<i>skipped question</i>							27

Concurrent Breakfast 3 - Breast Cancer Advances in Breast Cancer Care A/Prof Natasha Leigh							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	0	1	8	4	4.23	13
Speaker's delivery	0	0	1	5	7	4.46	13
Relevance	0	0	1	5	6	4.42	12
<i>answered question</i>							13
<i>skipped question</i>							31

Symposium 1: Advances in Lung Cancer Management - The Cost of Progress Advances in first line therapy Prof Tony Mok							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	2	5	18	10	4.03	35
Speaker's delivery	0	3	4	13	15	4.14	35
Relevance	0	1	4	18	11	4.15	34
<i>answered question</i>							35
<i>skipped question</i>							9

Symposium 1: Advances in maintenance therapy and beyond A/Prof Natasha Leigh							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	0	6	17	13	4.19	36
Speaker's delivery	0	0	3	17	16	4.36	36
Relevance	0	0	4	17	15	4.31	36
<i>answered question</i>							36
<i>skipped question</i>							8

Symposium 2: Neuroendocrine Tumours: Diagnosis, Treatment and Prognosis in 2011 and Beyond - Session 1 Recent advances in medical therapy for Neuroendocrine Tumours Prof Marianne Pavel							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	1	13	17	6	3.76	37
Speaker's delivery	1	2	12	15	7	3.68	37
Relevance	0	2	11	17	7	3.78	37
<i>answered question</i>							37
<i>skipped question</i>							7

Symposium 2: Multimodality Radio peptide Therapy of Disseminated Neuroendocrine Tumours Prof Harvey Turner							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	0	18	10	8	3.72	36
Speaker's delivery	0	3	15	10	7	3.60	35
Relevance	0	3	15	12	6	3.58	36
<i>answered question</i>							36
<i>skipped question</i>							8

Symposium 2: Open misere to royal flush; how do we choose between competing therapies for NET? Prof Rodney Hicks							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	1	0	15	10	8	3.71	34
Speaker's delivery	0	0	16	10	8	3.76	34
Relevance	0	1	14	10	8	3.76	33
<i>answered question</i>							34
<i>skipped question</i>							10

Oral Presentation Session 1 - Consultants Papers Abstracts							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	1	15	11	6	3.67	33
Speaker's delivery	1	0	15	11	6	3.64	33
Relevance	0	2	15	11	5	3.58	33
<i>answered question</i>							33
<i>skipped question</i>							11

Viewpoint Session - CAM Debate An expert on complementary and alternative medicine as essential member of a comprehensive cancer centre Ray Lowenthal and David Joske							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	1	7	13	10	4	3.26	35
Speaker's delivery	1	2	17	10	5	3.46	35
Relevance	1	4	13	12	4	3.41	34
<i>answered question</i>							35
<i>skipped question</i>							9

Oral Presentation Session 2 - Trainees Papers Abstracts							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	1	16	9	8	3.71	34
Speaker's delivery	0	1	20	5	8	3.59	34
Relevance	0	1	19	7	7	3.59	34
<i>answered question</i>							34
<i>skipped question</i>							10

Poster Walk Around Session							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	1	1	17	11	3	3.42	33
Speaker's delivery	1	0	22	5	2	3.23	30
Relevance	0	1	19	10	3	3.45	33
<i>answered question</i>							33
<i>skipped question</i>							11

Concurrent Breakfast 1 - Colorectal Cancer Multimodality treatment decision making in Rectal cancer A/Prof Deborah Schrag							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	0	7	8	4	3.84	19
Speaker's delivery	0	0	5	11	3	3.89	19
Relevance	0	0	6	10	3	3.84	19
<i>answered question</i>							19
<i>skipped question</i>							25

Concurrent Breakfast 2 - Neuroendocrine Tumours Strategy of the Treatment of NET in 2011 Prof Michel Ducreux							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	1	6	7	3	3.71	17
Speaker's delivery	0	1	6	4	6	3.88	17
Relevance	0	1	7	4	5	3.76	17
<i>answered question</i>							17
<i>skipped question</i>							27

Symposium 3 - Predictive and Prognostic: Making Sense of Bio-markers in Colorectal Cancer Prognostic and Predictive Markers in Colon Cancer: when and how they are used for treatment decision making in the USA A/Prof Deborah Schrag							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	0	6	18	9	4.09	33
Speaker's delivery	0	1	5	19	8	4.03	33
Relevance	0	1	4	19	9	4.09	33
<i>answered question</i>							33
<i>skipped question</i>							11

Symposium 3 - Biomarkers in colorectal cancer - How accurately do they mark? A/Prof Lara Lipton							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	2	10	15	7	3.79	34
Speaker's delivery	0	1	9	17	7	3.88	34
Relevance	0	1	13	14	6	3.74	34
<i>answered question</i>							34
<i>skipped question</i>							10

Symposium 3 - A pathologist's perspective on biomarkers in colorectal cancer Prof Paul Waring							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	2	17	13	2	3.44	34
Speaker's delivery	0	4	16	12	2	3.35	34
Relevance	0	6	12	14	1	3.30	33
<i>answered question</i>							34
<i>skipped question</i>							10

Symposium 4 - The Cost & Value of Treating Advanced Cancer with Non-Curative New Therapies Identifying High Value Cancer Treatments: Patient, Physician and Public Health System Perspectives A/Prof Deborah Schrag							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	0	8	14	11	4.09	33
Speaker's delivery	0	0	10	11	11	4.03	32
Relevance	1	0	11	11	10	3.88	33
<i>answered question</i>							33
<i>skipped question</i>							11

Symposium 4 - High cost drugs in Australia - Navigating between Evidence, Economics and Need A/Prof Jeremy Shapiro							
Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	1	9	13	9	3.94	32
Speaker's delivery	0	1	8	14	9	3.97	32
Relevance	0	1	9	10	12	4.03	32
<i>answered question</i>							32
<i>skipped question</i>							12

Plenary Session - Best of the Best Research in 2011 Abstracts

Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	1	10	15	8	3.88	34
Speaker's delivery	0	1	11	14	8	3.85	34
Relevance	0	0	11	16	7	3.88	34
<i>answered question</i>							34
<i>skipped question</i>							10

Symposium 5 - Neuroendocrine Tumours Diagnosis, Treatment and Progress in 2011 and beyond Prof Michel Ducreux

Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	0	12	12	6	3.80	30
Speaker's delivery	0	0	13	8	9	3.87	30
Relevance	0	1	11	11	7	3.80	30
<i>answered question</i>							30
<i>skipped question</i>							14

Symposium 5 - NET Cancer Management - Meeting our KPI's (Key Patient Indices) Dr John Leyden

Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	1	3	13	7	3	3.30	27
Speaker's delivery	0	5	15	4	3	3.19	27
Relevance	2	3	15	4	3	3.11	27
<i>answered question</i>							27
<i>skipped question</i>							17

Symposium 5 - Advancing the management of NETs in Australia Dr Yu Jo Chua

Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Met Expectations	0	2	13	7	5	3.56	27
Speaker's delivery	0	2	11	9	4	3.58	26
Relevance	0	2	11	9	5	3.63	27
<i>answered question</i>							27
<i>skipped question</i>							17

Overall Conference Evaluation

Answer Options	Poor	Fair	Good	Very Good	Excellent	Rating Average	Response Count
Scientific Program - Content & structure	0	1	11	20	9	3.90	41
Poster Display	0	9	17	10	3	3.18	39
USB - Usefulness & content	5	0	16	8	4	3.18	33
Exhibition	0	4	19	10	3	3.33	36
Social: Welcome Reception	0	3	13	9	1	3.31	26
Social: Gala Dinner	0	1	7	9	8	3.96	25
Cocktail Function	0	1	14	7	2	3.42	24
Overall organisation	0	1	9	21	9	3.95	40
Pre-Conference Information	0	6	14	15	5	3.48	40
Registration Process	0	2	14	18	6	3.70	40
Venue	0	2	10	23	5	3.78	40
Catering	0	1	15	19	5	3.70	40
<i>answered question</i>							41
<i>skipped question</i>							3

Scientific Program - Content & structure
Well balanced and interesting topics.
Good.
Seemed to bit a bit of overlap especially in the Neuroendocrine talks.
A fantastic meeting, great content, speakers well chosen.
Fair.
The scientific content was of good quality and I enjoyed Tony Mok and Natasha's presentations. Time keeping could be done better by the chairs.
Apart from Dr Schrag, the foreigners were pretty average and could have been replaced by more competent local presenters. We have got to get over our cultural cringe! There were no conflict of interest statements which were probably highly relevant. If we have numerous Australian presenters perhaps we would have a better turn up of consultants.
Too much of a focus on rare tumours eg NET.
Topical tumour groups chosen, NET was very interesting.
Poster Display
Great posters this year.
Easy to navigate.
Good.
No guide to where posters are.
Good although could have been more.
Good.
A bit redundant.
USB - Usefulness & content
Would appreciate also the speakers slides.
Good.
Useless. It would have been great to have lecture handouts where possible.
Excellent.
Unreliable.
Exhibition
Plenty of space.
Good.
Great.
Dull.
Good.
OK.
Social: Welcome Reception
Good for mixing.
Good.
Not much food.
Good.
Good.
Social: Gala Dinner
Stunning location, excellent meals and program.
Excellent venue and food. Correct mix of formal and informal.
Good.
The room was awkward and suffered from the lack of a dance floor or music to dance to.
Excellent venue & food.
Excellent venue.
Excellent venue; band a bit sedate.
Please advise what to wear before we fly into Adelaide.
YES! We managed to avoid the dreaded conga line this year.
Cocktail Function
Fine.
Good.
Very good.
Very good.
Food was average.
Good.
Felt ambushed by Unicorn foundation - would like a chance to talk to colleagues.
Please advise what to wear before we fly into Adelaide.

Overall organisation
Great !!
Good.
Excellent.
Superb.
Fair.
Good.
Pretty good apart from scientific program.

Pre-Conference Information
Adequate.
Good.
Excellent.
Fair.
Didn't receive information on program until conference started.
The information for poster presenters could be better as it was not clear whether it was meant to be landscape or portrait.
Fine.

Registration Process
Easy.
Good.
Easy.
Fair.
Information clear and process efficient.
Fine.

Venue
Excellent.
Good.
Very good.
Good.
Adelaide Convention Centre was a good venue for this conference.
A bit dull.
Difficult to navigate for such a small venue.

Catering
Fine.
Good.
Good. More vegetarian options would improve things.
Excellent.
Fair.
Good.
Catering was of good quality. Food was tasty.
Adequate.

At future conferences, what topics would you like to see covered?
Skin malignancies.
Case based discussions would be useful.
Supportive Care.
GIST, Melanoma.
Gynae cancers.
Gynaecology.
Prostate.
Please continue with the theme of treating rare cancers. The NET sessions were absolutely fantastic - I have learned a lot and built up confidence in looking after these patients. Could always have two themes - something common and something rare which is more didactic.
Difficult case discussion.
Sarcomas, Gynec Oncology, Germ Cell Tumours.
Head & neck cancer, safety aspects of chemotherapy/ biological drug delivery.
Sarcomas, Prostate Cancer.
More topics rather than repeating information about a smaller number of topics.
More local scientific work presentations.
Oncology practice/oncologists and palliative care work force/Use of cytotoxic drugs.
Education sessions for registrars
GIST.
GU cancer.

Other Comments
Good venue.
Very good conference overall.
It was very good overall!